Post-discontinuation, 19.6 % restarted the original medication, while 35 % adopted another option: alternative medication (27.4 %), healthcare visit for lifestyle modification (13.7 %), and metabolic and bariatric surgery (0.6 %)
Structural improvements in scar depth, skin laxity, and collagen density develop progressively over the series and continue to improve for three to six months after the final session
Research chemicals for laboratory use only Reserve Research sells peptides and research compounds strictly for in-vitro research use only
Because the compound activates four receptor subtypes, any preparation expressing more than one requires selective antagonists to interpret
Transitioning from weight loss to maintenance Determining goal weight achievement: Lost 10-12% body weight (cagrilintide alone) Lost 15-25% body weight (CagriSema) Weight stable for 4-8 weeks Satisfied with current weight Ready to focus on maintenance Maintenance dose options comparison: Option 1: Continue same dose Keep cagrilintide at 2.4mg weekly Ensures no regain Most conservative approach Highest cost Option 2: Reduce dose slightly Decrease to 1.8-2.0mg weekly Monitor weight for 4 weeks If stable, maintain If gaining, increase back 20-25% cost savings Option 3: Try every 10 days Instead of weekly, inject every 10 days Effectively 30% dose reduction Some maintain weight this way Requires close monitoring Recommendation: Try Option 2 first (reduce to 1.8-2.0mg)
When in doubt, consult a licensed medical provider who is knowledgeable in peptide-based therapies